AstraZeneca's Discovery Centre on the Cambridge Biomedical Campus. Health Tagrisso plus Orpathys cuts death risk by 32 percent in MET-driven lung cancer, Phase III SAFFRON trial shows Mono Scoops 2d Tagrisso plus Orpathys cut the risk of death by 32 percent and the risk of progression or death by 45 percent in MET-driven EGFR-mutated lung cancer after Tagrisso, in Phase III results presented at ESMO and published in The New England Journal of Medicine. Read Full Story
